Restless Legs Syndrome Market - Research Report, 2023by PSMR Industry Web Marketing
Restless legs syndrome increases at night when the patient is at rest. RLS are common in both, male and female; however the disease has its highest impact on woman who are elderly or in some cases woman with the age 35 to 50 years. Some of the most common symptoms of the restless legs syndrome are continue itching and pain in the legs, and unusual sleep pattern. The restless legs syndrome affects the quality of life of the person suffering from the disease.To know more about “Restless Legs Syndrome Market” visit: https://www.psmarketresearch.com/market-analysis/restless-legs-syndrome-market
The exact treatment of this disease is not present till now. However the available drug in the market helps in the indicative treatment of the disease. Some of the drug in the restless legs syndrome market such as sulfonamide by safinamide by Newron Pharmaceuticals reduces the symptoms by novel action such as potent, reversible and selective inhibition of MAO-B, without disturbing the MAO-A and dopamine uptake. This enhances the glutamate release and dopaminergic function of the patients; it also reduces the dopamine degradation. One other drug: SER-214 manufacture by Serina is used widely in the restless legs syndrome treatment; it uses a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology this drug can be combined with the polymer and transported to the patients.Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/restless-legs-syndrome-market/report-sample
Created on Sep 14th 2017 17:51. Viewed 297 times.